Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp15 | Calcium and Bone 1 | ECE2019

Recombinant human parathyroid hormone 1–84 for the treatment of adults with chronic hypoparathyroidism: Six-year safety and efficacy results of the RACE study

Bilezikian John P , Bone Henry , Clarke Bart L , Denham Douglas , Germak John , Lee Hak-Myung , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey G , Sherry Nicole , Shoback Dolores M , Vokes Tamara J , Warren Mark L , Watts Nelson B

Background: RACE is an open-label study that assessed the long-term safety and efficacy of recombinant human parathyroid hormone 1–84 (rhPTH[1–84]) for the treatment of hypoparathyroidism in adults (ClinicalTrials.gov identifier NCT01297309). Here, we present 6-year safety and efficacy data.Methods: Patients initially received 25 or 50 μg of rhPTH(1–84) subcutaneously, once daily, with stepwise dose adjustments of 25 μg (up or do...

ea0049gp47 | Bone & Calcium Homeostasis 2 | ECE2017

Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study

Clarke Bart L , Vokes Tamara J , Bilezikian John P , Bone Henry G , Denham Douglas S , Lee Hak-Myung , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey G , Shoback Dolores M , Warren Mark L , Watts Nelson B , Krasner Alan

Hypoparathyroidism (HPT) is characterised by hypocalcaemia and impaired renal phosphate excretion and calcium conservation. Oral calcium supplements and calcitriol can improve serum calcium levels but lack the physiologic effects of PTH on renal reabsorption of calcium. RACE is an ongoing open-label study evaluating the long-term safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84], parathyroid hormone rDNA) in adults with HPT (NCT01297309). In this interim analys...

ea0006p52 | Bone | SFE2003

sRANK-L AND OPG ARE INCREASED IN SOME OSTEOPOROTIC PATIENTS

Jabbar S , Weston C , Drury J , Varey J

The importance of the sRANK-L / RANK / Osteoprotegerin (OPG) system in osteoclast function has clearly been demonstrated in the rat. Activating and inactivating mutations lead to severe disturbances of bone remodelling.Since this early animal work, there have been several studies designed to assess the importance of sRANK-L / RANK / OPG in diseases of the human skeleton. sRANK-L and OPG are measurable in blood.This cross-sectional ...

ea0029p1226 | Obesity | ICEECE2012

Curcumin inhibits the upregulation of cathepsin L by palmitate in fat

Yoo J. , Lee Y. , Kim J. , Kang S. , Nam J. , Park J. , Ahn C. , Song Y. , Kim K.

Objective: Cathepsin L can control adipogenesis and relate to acute coronary syndrome. However, it is not clear whether cathepsin L can be affected by saturated fatty acid and decrease by curcumin. We examined the hypothesis that palmitate upregulates cathepsin L expression in adipose tissue and curcumin can be block that effect.Methods: 3T3-L1 cells were fully differentiated for 8 to 10 days and treated with palmitate, LPS, IL6, TNF-α, IL6 neutrali...

ea0086op4.2 | Metabolism, Obesity and Diabetes | SFEBES2022

Differential effects of L- and D-lactate on HCAR1 signalling

Milner Annabelle , Brown Alastair , Frost Gary , Hanyaloglu Aylin

Lactate is a metabolite that activates the G-protein coupled receptor, Hydroxycarboxylic acid Receptor 1 (HCAR1) to regulate physiological processes such as lipolysis, cancer cell survival, and neuroprotection. Lactate exists in two forms, L+ and D-, with the L isoform predominant in the human body. Interestingly, both isoforms are only found together in the gastrointestinal tract. L-lactate is synthesised as a by-product of anaerobic respiration, whereas D-lactate, is a produ...

ea0014p376 | (1) | ECE2007

Increase of L-thyroxine requirement during pregnancy

Russo Laura , Tonacchera Massimo , Gianetti Elena , Vitti Paolo , Pinchera Aldo

In pregnant women with a thyroid disease an increased amount of LT4 may be required for the correction of hypothyroidism or treatment of nodular goiter.Aim of this study was to assess the amount of the variations of LT4 requirement in pregnant women with thyroid diseases.To address this issue, we retrospectively evaluated a cohort of 138 women treated with LT4 divided in two groups: 47 euthyroid (E) (affected by nodular goiter (NG)...

ea0029p1711 | Thyroid (non-cancer) | ICEECE2012

L-Thyroxine therapy and depression in subclinical hypothyroidism

Unal M. , Yazgan Aksoy D. , Cinar N. , Okan Yildiz B. , Bayraktar M. , Usman A.

Background and aim: Subclinical hypothyrodism (SH) appears to be associated with mood and changes. The aims of this study were: i) to determine whether depression is more common in SH, and ii) to investigate the effects of L-thyroxine (LT4) therapy on depressive symptoms.Methods: 31 patients with SH and 36 age amd BMI matched healthy controls were included. Beck and Hamilton scales were used to evaluate depression...

ea0081p50 | Calcium and Bone | ECE2022

Impact of chronic hypoparathyroidism on symptom severity and interference with life as reported by patients treated with recombinant human parathyroid hormone (1-84), rhpth(1-84)

Clarke Bart L. , Hadker Nandini , Athavale Amod , Kolev Irana , Ayodele Olulade

Chronic hypoparathyroidism is a rare mineral homeostasis disorder managed by conventional therapy (oral calcium and active vitamin D), alone or with adjunctive rhPTH(1-84). Chronic hypoparathyroidism is associated with considerable symptom burden, which can interfere with daily living. We report results from a web-based, cross-sectional survey conducted among adults with chronic hypoparathyroidism. The objectives were to quantify the impact on overall life interference of (1) ...

ea0026s28.3 | Polycystic ovary syndrome: classification, genetics and therapy | ECE2011

PCOS: treatment of infertility and prediction of success

Fauser Bart

Polycystic ovary syndrome is a complex genetic condition, diagnosed based on oligo/anovulation, hyperandrogenemia and polycystic ovaries. Moreover, these women frequently present with obesity, insulin resistance and other signs of metabolic disease. In a gynaecology practice, the great majority of PCOS women present with anovulatory infertility. In fact, it is often suggested that around 20–30% of all infertility is due to PCOS. The medical treatment aiming to restore nor...

ea0015s37 | Inflammation and the adipocyte - integrated pathways that regulate disease risk | SFEBES2008

Nuclear receptors and regulation of inflammatory pathways

Staels Bart

Cardiovascular disease is significantly increased in patients with the metabolic syndrome and type 2 diabetes. A clustering of risk factors, including dyslipidemia, insulin resistance, hypertension, inflammation and coagulation disorders result in an increased risk for cardiovascular events in these patients. PPARs (Peroxisome Proliferator-Activated Receptors) and LXRs are ligand-activated transcription factors that control lipid and glucose metabolism, as well as the inflamma...